ArticleBMC gastroenterology2026
Tacrolimus therapy for ulcerative colitis: a retrospective study of factors associated with inducing and maintaining remission.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTacrolimus (TAC) is highly effective pharmacotherapy for refractory ulcerative colitis. However, the factors involved in achieving and maintaining remission are unclear, and the optimal maintenance therapy after inducing remission with TAC remains in question.
methodsThis study involved 136 patients with ulcerative colitis who received TAC therapy from April 2009 to December 2021. The study examined the remission induction rate, overall and drug-specific remission maintenance rates after 52 weeks, factors associated with remission and maintenance, and adverse events.
resultsThe overall remission rate was 72.7%, with significant differences by sex, endoscopic scores before and after TAC therapy, prior experience with biologic therapy, previous biologic therapy, post-TAC Lichtiger Colitis Activity Index (CAI) score, and LCAI reduction at 52 weeks. The remission maintenance rate at 52 weeks was 51.5% and differed significantly by sex, prior experience with biologic therapy, length of hospital stay, and total prednisolone dose during hospitalization. The 52-week maintenance rates by medication were 67% for azathioprine, 54% for TAC, and 37% for biologic agents. No serious side effects were observed with TAC therapy.
conclusionsTAC therapy effectively induced remission in patients with refractory ulcerative colitis. Findings also suggested that such remission can be maintained for up to 52 weeks by treating with either TAC or a biologic agent after inducing remission, even if azathioprine cannot be used as maintenance therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.